Noguchi, Masanori <br/><br/>
Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.  [electronic resource] 

 -  The Prostate  Jun 2012 
 - 834-45 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1097-0045 
<br/><br/><label>Standard No.: </label>10.1002/pros.21485  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Cancer Vaccines--therapeutic use<br/>Cytokines--blood<br/>Disease Progression<br/>Docetaxel<br/>Humans<br/>Immunity, Humoral<br/>Interleukin-6--blood<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Orchiectomy<br/>Precision Medicine<br/>Prospective Studies<br/>Prostatic Neoplasms--drug therapy<br/>Taxoids--therapeutic use<br/>Treatment Failure<br/>Treatment Outcome